Table 2.
Characteristics of available meta-analyses on the relationship between SC-HPT and cardiovascular (CV) morbidity and mortality. MACE = major cardiovascular events
| Inclusion criteria | Haentjens et al. [18] (12) | Ochs et al. [19] (13) | Singh et al. [21] (15) | Collet et al. [26] (28) | Gencer et al. [23] (17) | Yang et al. [35] (29) | Sun et al. [24] (18) | Du Puy et al. [28] (25) | Sonh et al. [13] (10) |
|---|---|---|---|---|---|---|---|---|---|
| N. of included studies | 9 | 12 | 6 | 10 | 6 | 17 | 16 | 4 | 37 |
| N. of analyzed patients | 14,912 | 14,449 | 14,386 | 52,674 | 25,390 | 52,808 | 71,808 | 2,116 | 1,626,005 |
| Age mean/range (years) | – | 18–95 | 17–89 | 59 | 21–100 | 49–85 | 45.4–85 | 80–109 | 51.3–85.5 |
| Follow Up mean/range (years) | 2–20 | 2–20 | 4–20 | 8.8 | 2–16.3 | 2–20 | 3.2–20 | 5 | – |
|
TSH cut off mU/L Subclinical hyperthyroidism |
0.3–0.5 | 0.3–0.5 | 4–5 | 0.45 | 0.45 | 0.1–0.5 | 0.25–0.5 | 0.3 | – |
| Yes | No | Yes | No | Yes | No | Yes | No | Yes | No | Yes | No | Yes | No | Yes | No | Yes | No | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Unadjusted risk | X | X | X | X | X | X | X | X | X | |||||||||
| Adjusted risk | X | X | X | X | X | X | X | X | X | |||||||||
| Age stratified risk | X | X | X | X | X | X | X | X | X | |||||||||
| TSH stratified risk | X | X | X | X | X | X | X | X | X | |||||||||
| CV events analyzed | ||||||||||||||||||
| MACE | X | X | X | X | X | X | X | X | ||||||||||
| Coronary events | X | X | X | X | X | X | X | X | X | |||||||||
| Atrial fibrillation | X | X | X | X | X | X | X | X | X | |||||||||
| Heart failure | X | X | X | X | X | X | X | X | X | |||||||||
| CV mortality | X | X | X | X | X | X | X | X | X | |||||||||
| Total mortality | X | X | X | X | X | X | X | X | X |